Monte Rosa Therapeutics

GLUE

15.3806.90% ( -1.140 )

Closed: Aug 3, 16:00:00 (EDT)

Monte Rosa Therapeutics

GLUE

15.3806.90% ( -1.140 )

Closed: Aug 3, 16:00:00 (EDT)

Forecast & Rating8 analysts currently cover Monte Rosa Therapeutics, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $30.67, about 99.4% upside from the current price of $15.38. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 21.3% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Monte Rosa Therapeutics closely still see room for the stock to rise. Data as of Aug 1, 2026; for reference only and not investment advice.

Jul 31, 2026

Price forecast

$30.6799.39%

Forecast & RatingStrong buy

8analysts

Strong buy75.00%
Buy25.00%
Hold0.00%
Sell0.00%
Strong sell0.00%

Target price forecast

Forecast baselineAug 2, 2026

Forecast met38.1%

Stock price$15.38

Average forecast price$22.7

Highest forecast price$28

Lowest forecast price$16

Analyst ratings

Strong buy

Buy

Hold

Sell

Strong sell

Source: S&P Global

This information is for reference only and is not investment advice.

Forecast & Rating8 analysts currently cover Monte Rosa Therapeutics, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $30.67, about 99.4% upside from the current price of $15.38. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 21.3% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Monte Rosa Therapeutics closely still see room for the stock to rise. Data as of Aug 1, 2026; for reference only and not investment advice.